InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

44.7/100

Rank #1,902 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

GSK Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for GSK plc (GSK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GSK at 44.7/100 on a 32-signal composite quality model, placing it at rank #1,902 of 2,961 stocks — the bottom half of the AI-ranked universe. Top institutional holders of GSK by reported 13-F value include FMR, DODGE & COX, Fisher Asset Management, based on the most recent SEC filings. GSK trades on the NYSE exchange and files with the SEC under CIK 1131399. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GSK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GSK plc directly from SEC EDGAR. GSK plc's 13F Pro composite quality score has ranged between 44 and 48 since 2026, currently 44.7 — a stable long-term trajectory across 47 quarterly and live scoring snapshots.

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.1% YoY
$32.67BFY 2025
FY22 $29.32BFY23 $30.33BFY24 $31.38BFY25 $32.67B

Total Assets

+2.8% YoY
$61.12BFY 2025
FY22 $60.15BFY23 $59.01BFY24 $59.46BFY25 $61.12B

Get alerted when GSK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GSK plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of GSK

Companies Similar to GSK

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

AZN

ASTRAZENECA PLC

47
AI score
Shared smart-money ownership · 3 shared holders
RIO

RIO TINTO PLC

44
AI score
Shared smart-money ownership · 14 shared holders
PHG

KONINKLIJKE PHILIPS NV

40
AI score
Similar quality profile · 8 shared holders
NVO

NOVO NORDISK A S

52
AI score
Shared smart-money ownership · 9 shared holders
HLN

Haleon plc

44
AI score
Shared smart-money ownership · 24 shared holders
TAK

TAKEDA PHARMACEUTICAL CO LTD

37
AI score
Similar quality profile · 7 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put GSK on your watchlist

Track score changes the day GSK plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is GSK a good stock to buy?

13F Pro's AI-powered analysis of GSK plc (GSK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GSK are available on the GSK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GSK is classified as a mega company.

Which hedge funds own GSK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GSK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GSK plc's investment landscape.